CAPR earnings: next report 2026-08-11, real EPS beat/miss history, analyst consensus Buy, P/E -8.15. Updated 2026-07-23.
Capricor Therapeutics (CAPR) Research Hub
Capricor Therapeutics (CAPR) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 8.37 USD (-3.13%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -8.15, market cap 0.88B. This hub links to the full technical, earnings and options research available for CAPR.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 8.37 USD (-3.13%) |
| 52-week range | 2.96 USD – 30.19 USD |
| Trend regime | Range |
| 14-day RSI | 68.6 (Bullish) |
| Trailing P/E | -8.15 |
| Market cap | 0.88B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-11 |
Available research for CAPR
Covered Call on CAPR: how it works, illustrative setup around the real 8.37 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CAPR: how it works, illustrative setup around the real 8.37 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CAPR: how it works, illustrative setup around the real 8.37 USD price, max profit/loss, breakeven and when to use it. Educational.
CAPR technical analysis: range, last 8.37 USD, RSI 68.6, 52w range 2.96 USD–30.19 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is CAPR in?
Capricor Therapeutics (CAPR) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CAPR in an uptrend or downtrend?
As of 2026-09-11, CAPR is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CAPR's trailing P/E ratio?
CAPR's trailing P/E is -8.15, with a market cap of 0.88B. See the earnings research page for full valuation detail.
When does CAPR next report earnings?
CAPR is next scheduled to report earnings on 2026-08-11, with a consensus EPS estimate of -0.58 USD.